Capnia Inc Share Price Nasdaq
Equities
US14066L1052
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-13 | Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating | MT |
05-10 | Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target | MT |
Sales 2024 * | - | Sales 2025 * | 44.75M 3.51B | Capitalization | 1.5B 118B |
---|---|---|---|---|---|
Net income 2024 * | -96M -7.53B | Net income 2025 * | -61M -4.79B | EV / Sales 2024 * | - |
Net cash position 2024 * | 238M 18.69B | Net cash position 2025 * | 151M 11.87B | EV / Sales 2025 * | 30.1 x |
P/E ratio 2024 * |
-16.3
x | P/E ratio 2025 * |
-26.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.86% |
Latest transcript on Capnia Inc
Managers | Title | Age | Since |
---|---|---|---|
Anish Bhatnagar
CEO | Chief Executive Officer | 56 | 31/12/05 |
James Mackaness
DFI | Director of Finance/CFO | 60 | 13/11/19 |
Ernest Mario
CHM | Chairman | 85 | 02/08/07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ernest Mario
CHM | Chairman | 85 | 02/08/07 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 25/04/19 |
Bill Harris
BRD | Director/Board Member | 65 | 01/06/14 |
1st Jan change | Capi. | |
---|---|---|
+11.96% | 116B | |
+12.93% | 106B | |
-9.69% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-14.54% | 16.33B | |
+6.58% | 14.14B | |
+30.64% | 12.02B |